selected publications
- Integrative Transcriptomic and Single-Cell Protein Characterization of Colorectal Carcinoma Delineates Distinct Tumor Immune Microenvironments Associated with Overall Survival. 2024 GET IT
- Transferrin receptor-based circulating tumor cell enrichment provides a snapshot of the molecular landscape of solid tumors and correlates with clinical outcomes. 2024 GET IT
- Ischemic Stroke with Comorbid Cancer Has Specific miRNA-mRNA Networks in Blood That Vary by Ischemic Stroke Mechanism. Annals of neurology. 2024 Academic Article GET IT
- A Randomized Trial of Two Remote Healthcare Delivery Models on the Uptake of Genetic Testing and Impact on Patient-Reported Psychological Outcomes in Families With Pancreatic Cancer: The Genetic Education, Risk Assessment, and Testing (GENERATE) Study. Gastroenterology. 2024 Academic Article GET IT
- Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer. Oncogene. 2023 Academic Article GET IT
- Giving information strategically and transparently: A pilot trial of the Oncolo-GIST intervention to promote patients' prognostic understanding. Cancer medicine. 2023 Academic Article GET IT
- Ischemic Stroke with Cancer: Hematologic and Embolic Biomarkers and Clinical Outcomes. Journal of thrombosis and haemostasis : JTH. 2022 Academic Article GET IT
- A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond. Cancer medicine. 2022 Academic Article GET IT
- Twitter Conversations About Pancreatic Cancer by Health Care Providers and the General Public: Thematic Analysis. JMIR cancer. 2022 Academic Article GET IT
- Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. Cancer prevention research (Philadelphia, Pa.). 2021 Academic Article GET IT
- A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma. Investigational new drugs. 2021 Academic Article GET IT
-
Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage.
Communications biology.
2021
Academic Article
GET IT
Times cited: 5 -
Mechanisms of Ischemic Stroke in Patients with Cancer: A Prospective Study.
Annals of neurology.
2021
Academic Article
GET IT
Times cited: 1 -
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
Annals of oncology : official journal of the European Society for Medical Oncology.
2021
Academic Article
GET IT
Times cited: 4 -
Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020
Academic Article
GET IT
Times cited: 9 -
Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS-Mutated Colorectal Cancer.
Molecular cancer therapeutics.
2020
Academic Article
GET IT
Times cited: 17 - A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer. Journal of pancreatic cancer. 2019 Academic Article GET IT
-
Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.
JCO precision oncology.
2019
Academic Article
GET IT
Times cited: 32 -
Cancer-Related Ischemic Stroke Has a Distinct Blood mRNA Expression Profile.
Stroke.
2019
Academic Article
GET IT
Times cited: 13 -
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.
Cancer discovery.
2018
Academic Article
GET IT
Times cited: 675 - Clinical laboratory and imaging evidence for effectiveness of agarose-agarose macrobeads containing stem-like cells derived from a mouse renal adenocarcinoma cell population (RMBs) in treatment-resistant, advanced metastatic colorectal cancer: Evaluation of a biological-systems approach to cancer therapy (U.S. FDA IND-BB 10091; NCT 02046174, NCT 01053013). Chinese journal of cancer research = Chung-kuo yen cheng yen chiu. 2018 Academic Article GET IT
-
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2017
Academic Article
GET IT
Times cited: 59 -
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
Cancer.
2017
Academic Article
GET IT
Times cited: 54 -
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2017
Academic Article
GET IT
Times cited: 304 -
Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2016
Academic Article
GET IT
Times cited: 51 - First-in-Human Phase 1 Trial of Agarose Beads Containing Murine RENCA Cells in Advanced Solid Tumors. Cancer growth and metastasis. 2016 Academic Article GET IT
-
Chemotherapy dose intensity predicted by baseline nutrition assessment in gastrointestinal malignancies: A multicentre analysis.
European journal of cancer.
2016
Academic Article
GET IT
Times cited: 20 -
Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2015
Academic Article
GET IT
Times cited: 112 -
Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.
Clinical genitourinary cancer.
2015
Academic Article
GET IT
Times cited: 45 -
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.
European journal of cancer.
2015
Academic Article
GET IT
Times cited: 15 -
Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver.
Nature cell biology.
2015
Academic Article
GET IT
Times cited: 2041 -
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2015
Academic Article
GET IT
Times cited: 239 -
Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation.
Nature communications.
2015
Academic Article
GET IT
Times cited: 87 -
Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach.
Investigational new drugs.
2014
Academic Article
GET IT
Times cited: 12 -
Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.
Cancer.
2012
Academic Article
GET IT
Times cited: 79 -
Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach.
Clinical breast cancer.
2011
Information Resource
GET IT
Times cited: 100 -
Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma.
Clinical colorectal cancer.
2010
Academic Article
GET IT
Times cited: 8 -
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.
Cancer chemotherapy and pharmacology.
2010
Academic Article
GET IT
Times cited: 23 -
Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma.
American journal of clinical oncology.
2010
Academic Article
GET IT
Times cited: 43 -
A phase I trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma.
American journal of clinical oncology.
2010
Academic Article
GET IT
Times cited: 14 -
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2008
Academic Article
GET IT
Times cited: 447 -
Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.
2004
Information Resource
GET IT
Times cited: 122